J Korean Ophthalmol Soc.  2006 Mar;47(3):443-448.

The Effect of L-dopa in Amblyopic Children for Whom Occlusion Therapy Failed

Affiliations
  • 1Department of Ophthalmology, Korea University College of Medicine, Seoul, Korea. earth 317@yahoo.co.kr
  • 2Department of Neurology, Korea University College of Medicine, Seoul, Korea.

Abstract

PURPOSE: This study was undertaken to evaluate the effect of L-dopa in amblyopic children for whom occlusion treatment failed.
METHODS
We studied nine amblyopic children (11 eyes) for whom part-time occlusion (4~8 hours/day) treatment for a minimum period of 6 months had failed. The types of amblyopia included: anisometropic (1 patient, 1 eye), stimulus deprivation (4 patients, 6 eyes) and mixed (anisometropic and strabismic: 2 patients, 2 eyes; anisometropic and organic: 2 patients, 2 eyes). Best corrected visual acuity before treatment was between 0.05 and 0.5. They received, with full informed consent of the parent, levodopa (2~4 mg/kg) for 8 weeks combined with part-time occlusion.
RESULTS
The children were between 4 and 11 years old (mean 5.8+/-2.05). Of the subjects, 45.5% (4 patients, 5 eyes) had improved visual acuity after 8 weeks of treatment. In one patient with anisometropic, two patients with mixed (anisometropic and strabismic), and one patient with stimulus deprivation (ametropic) amblyopia, visual acuity improved by one to five lines.
CONCLUSIONS
In anisometropic, strabismic amblyopes and mild deprivational amblyopes for whom occlusion treatment failed, L-dopa improved visual acuity. L-dopa may be an additional option for treatment of amblyopic patients with a guarded visual prognosis.

Keyword

Anisometropic amblyopia; Deprivational amblyopia; L-dopa; Strabismic amblyopia

MeSH Terms

Amblyopia
Child*
Humans
Informed Consent
Levodopa*
Parents
Prognosis
Visual Acuity
Levodopa
Full Text Links
  • JKOS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr